Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Radioresistance of KRAS/TP53‐mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo

30 Jul 2019

Abstract excerpt

Recent clinical data have linked KRAS/TP53 comutation (mut) to resistance to radiotherapy (RT), but supporting laboratory in vivo evidence is lacking. In addition, the ability of different radiation doses, with/without epidermal growth factor receptor (EGFR)‐directed treatment, to achieve local tumor control as a function of KRAS status is unknown. Here, we assessed clonogenic radiation survival of a panel of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatocellular Carcinoma Treatment and Prognosis
Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31359406
DOI: 10.1002/ijc.32598

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Radioresistance of KRAS/TP53‐mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivoPMID 31359406Read ↗

A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 statusSemantic proximity Read ↗

Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.Semantic proximity Read ↗

Targeting K-Ras-mediated DNA damage response in radiation oncology: Current status, challenges and future perspectivesSemantic proximity Read ↗

A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer.Semantic proximity Read ↗

Radiosensitization of Glioblastoma by the K-ras Inhibitor RMC-6236Semantic proximity Read ↗

Radio-sensitization of mutated KRAS G12C non-small cell lung cancer with KRAS G12C tyrosine kinase inhibitor and Carbon ions irradiationSemantic proximity Read ↗

Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair.Semantic proximity Read ↗

Radiosensitivity in lung cancer with focus on p53: a review based on a doctoral thesis.Semantic proximity Read ↗

KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partnerSemantic proximity Read ↗

Assessing the Radiation Response of Lung Cancer with Different Gene Mutations Using Genetically Engineered MiceSemantic proximity Read ↗

Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.